Canaccord Genuity Maintains Buy on Definium Therapeutics, Lowers Price Target to $58
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ: DFTX ) with a Buy and lowers the price target from $60 to $58.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.